4P Real-world outcomes of a trastuzumab emtansine (T-DM1) biosimilar (Ujvira) in early-stage HER2-positive breast cancer: A single-centre retrospective study from India

Key Points

• This study aims to evaluate the real-world outcomes of a T-DM1 biosimilar in early-stage HER2-positive breast cancer patients, focusing on invasive disease-free survival and safety.
• Conducted as a retrospective study at a single centre in India.
• Evaluated outcomes of a trastuzumab emtansine biosimilar after neoadjuvant therapy.
• Assessed key metrics such as invasive disease-free survival (IDFS) and safety.
• Found improvements in invasive disease-free survival (IDFS) with the T-DM1 biosimilar.
• Noted acceptable safety outcomes in routine clinical practice.
• Results indicate potential benefits for patients in low-resource settings.

Abstract